AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients…
Ear Nose Throat Disorders
-
-
Armata completes Phase II Tailwind study enrollment in US
Armata Pharmaceuticals has completed patient enrollment for its Phase II Tailwind study for inhaled bacteriophage therapy AP-PA02, targeting chronic pulmonary…
-
Pipeline Moves: Pfizer’s oral Nurtec approval prospects rise after Phase II/III completion
This week on Pipeline Moves, we kick off by looking at the completion of a Phase II/III trial of Pfizer’s…
-
Regeneron’s gene therapy triumphs twice, restoring hearing in children
Regeneron Pharmaceuticals’ gene therapy for otoferlin hearing loss, DB-OTO, has restored hearing to normal in an 11-month-old child within 24…
-
Sensorion’s SENS-401 meets secondary endpoints in Phase IIa hearing trial
France-based Sensorion has announced that its hearing loss candidate SENS-401 has a protective effect on early residual hearing loss after…
-
Sensorion unveils promising initial results from trial of SENS-401
Sensorion has unveiled promising preliminary results from its Proof of Concept (POC) Phase IIa trial of SENS-401 (Arazasetron) for the…
-
Altamira’s Bentrio nasal spray trial meets primary efficacy endpoint
Altamira Therapeutics has reported that the NASAR clinical trial of Bentrio nasal spray for seasonal allergic rhinitis (SAR) has met…
-
Lyra restarts second pivotal Phase III trial of LYR-210 nasal implant
Lyra Therapeutics has restarted screening and enrolment of patients in its second pivotal Phase III clinical trial, ENLIGHTEN II, of…
-
MHRA authorises Decibel’s CTA for trial of DB-OTO in paediatric patients
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Decibel Therapeutics’ clinical trial application (CTA) for initiating a…
-
Sensorion reports first patient enrolment in Phase IIa ototoxicity trial
Sensorion has reported the enrolment of the first patient in its Phase IIa proof of concept clinical trial of SENS-401…
